Schlagwörter
DABRAFENIB
4
IMPACT
4
MULTICENTER
4
Oncology
4
VEMURAFENIB
4
advanced melanoma
4
survival
4
systemic therapy
4
AGE
2
COVID-19
2
DOUBLE-BLIND
2
Dermatology
2
Environmental and Occupational Health
2
General Biochemistry
2
Genetics and Molecular Biology
2
Health Policy
2
Hematology
2
IMMUNOTHERAPY
2
IPILIMUMAB
2
Immune checkpoint inhibitors
2
METASTATIC MELANOMA
2
Metastatic melanoma
2
NIVOLUMAB
2
Older patients
2
Outcome
2
POOLED ANALYSIS
2
Public Health
2
STAGE-III
2
Safety
2
Targeted therapy
2
braf
2
center variation
2
clinical outcomes
2
combined nivolumab
2
dabrafenib
2
double-blind
2
dutch melanoma treatment registry
2
ipilimumab
2
metastatic melanoma
2
multicenter
2
nationwide registry
2
open-label
2
phase-3
2
surgery
2